Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors

被引：20

作者：

Isaacs, Michelle ^{[1
]}

Tonks, Katherine T. ^{[1
,2
,3
]}

Greenfield, Jerry R. ^{[1
,2
,3
]}

机构：

[1] Univ New South Wales, St Vincents Hosp, Dept Endocrinol & Diabet, Sydney, NSW, Australia

[2] Univ New South Wales, Garvan Inst Med Res, Diabet & Metab Div, Sydney, NSW, Australia

[3] Univ New South Wales, Fac Med, Sydney, NSW, Australia

来源：

INTERNAL MEDICINE JOURNAL | 2017年 / 47卷 / 06期

关键词：

diabetic ketoacidosis; diabetes mellitus; type; 2; sodium-glucose transporter 2; hypoglycaemic agents; humans; EMPAGLIFLOZIN;

D O I：

10.1111/imj.13442

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are an increasingly prescribed class of medication for type 2 diabetes mellitus. Euglycaemic diabetic ketoacidosis (euDKA) has been reported in association with SGLT2i use. Clinicians need to understand how to recognise and treat this complication. We describe three cases of euDKA in patients treated with SGLT2i.

引用

页码：701 / 704

页数：4

共 9 条

[1]

Australian Government Department of Health, PBS EXP PRESCR 12 MO

[2]

Australian Government Department of Health, DAT ADV EV NOT MED

[3] Lessons from the bedside: ketoacidosis and SGLT2 inhibitors [J].

Chow, Yvonne Y. ;

Worsley, Roisin ;

Topliss, Duncan J. .

MEDICAL JOURNAL OF AUSTRALIA, 2016, 205 (04) :191-192

[4] AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS [J].

Handelsman, Yehuda ;

Henry, Robert R. ;

Bloomgarden, Zachary T. ;

Dagogo-Jack, Sam ;

DeFronzo, Ralph A. ;

Einhorn, Daniel ;

Ferrannini, Ele ;

Fonseca, Vivian A. ;

Garber, Alan J. ;

Grunberger, George ;

LeRoith, Derek ;

Umpierrez, Guillermo E. ;

Weir, Matthew R. .

ENDOCRINE PRACTICE, 2016, 22 (06) :753-762

[5] Hyperglycemic Crises in Adult Patients with Diabetes [J].

Kitabchi, Abbas E. ;

Umpierrez, Guillermo E. ;

Miles, John M. ;

Fisher, Joseph N. .

DIABETES CARE, 2009, 32 (07) :1335-1343

[6] SGLT2 Inhibitors May Predispose to Ketoacidosis [J].

Taylor, Simeon I. ;

Blau, Jenny E. ;

Rother, Kristina I. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (08) :2849-2852

[7]

Wanner C, 2016, NEW ENGL J MED, V375, P1801, DOI [10.1056/NEJMoa1515920, 10.1056/NEJMc1611290]

[8] The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes [J].

Whalen, Karen ;

Miller, Shannon ;

St Onge, Erin .

CLINICAL THERAPEUTICS, 2015, 37 (06) :1150-1166

[9] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes [J].

Zinman, Bernard ;

Wanner, Christoph ;

Lachin, John M. ;

Fitchett, David ;

Bluhmki, Erich ;

Hantel, Stefan ;

Mattheus, Michaela ;

Devins, Theresa ;

Johansen, Odd Erik ;

Woerle, Hans J. ;

Broedl, Uli C. ;

Inzucchi, Silvio E. ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22) :2117-2128

← 1 →